Xuriden

Indicated For

hereditary orotic aciduria

About This Medication

# BTG International Inc. Patient Assistance Program Guide: How to Get Xuriden (uridine triacetate) at Low or No Cost Xuriden (uridine triacetate) oral granules is a specialized medication used to treat **hereditary orotic aciduria (HOA)**, a rare genetic disorder affecting uridine production in the body. This guide explains the **BTG International Inc. Patient Assistance Program (PAP)**, which provides free or low-cost Xuriden to eligible patients who cannot afford it, helping ensure access to this life-saving therapy.[2][9] ## About Xuriden and Hereditary Orotic Aciduria **Hereditary orotic aciduria** is an ultra-rare autosomal recessive disorder caused by a deficiency in the enzyme uridine monophosphate synthase (UMPS), leading to inadequate uridine synthesis. This results in excessive orotic acid buildup, causing symptoms like severe anemia, failure to thrive in children, developmental delays, and megaloblastic anemia resistant to vitamin B12 or folate.[4][6][8] **Xuriden** is an acetylated form of uridine—a pyrimidine analog that delivers uridine systemically after oral administration. It reduces orotic acid overproduction through feedback inhibition and replenishes uridine levels. Approved by the FDA for adults and pediatric patients with HOA, it is typically prescribed by metabolic disease specialists. Dosing is weight-based (e.g., 60 mg/kg once daily), mixed with applesauce or formula, and requires prior authorization from most insurers due to its specialty status.[5][6][8] Without treatment like Xuriden, patients face life-threatening complications. Early diagnosis via genetic testing (biallelic UMPS variants) or clinical findings (elevated urinary orotic acid, megaloblastic anemia) is crucial.[4][5] ## Who Qualifies for the Program? The **BTG International Inc. PAP** offers free medication to uninsured or underinsured patients who meet financial need criteria and have a confirmed HOA diagnosis. While specific income thresholds are not publicly detailed, programs like this typically target those at or below **400-500% of the Federal Poverty Level (FPL)**, prioritizing low-income, uninsured, or Medicare Part D patients facing high out-of-pocket costs.[2][9] Key eligibility factors include: - Prescription for Xuriden from a licensed healthcare provider (ideally a metabolic specialist). - U.S. residency and valid Social Security number. - Inability to afford the medication after insurance (if applicable). - No concurrent use with similar drugs like Vistogard (also uridine triacetate, for different indications).[7][8] Patients with Medicare Part D should contact the program directly, as it may provide co-pay assistance or full coverage for eligible individuals.[9] ## Income Eligibility Breakdown Exact thresholds vary and should be confirmed with BTG, but similar programs use FPL guidelines. Below is a general table based on 2026 U.S. FPL (adjusted annually; check HHS.gov for updates). Assume eligibility up to 400% FPL for illustration—call to verify. | Household Size | 100% FPL | 200% FPL | 300% FPL | 400% FPL | 500% FPL | |----------------|----------|----------|----------|----------|----------| | 1 (Individual) | $15,060 | $30,120 | $45,180 | $60,240 | $75,300 | | 2 (Couple) | $20,440 | $40,880 | $61,320 | $81,760 | $102,200| | 3 | $25,820 | $51,640 | $77,460 | $103,280| $129,100| | 4 | $31,200 | $62,400 | $93,600 | $124,800| $156,000| *Notes: Add ~$5,380 per additional person. Assets may be reviewed. Medicare Extra Help qualifiers often auto-qualify.*[3] ## Insurance Requirements - **Commercial/Private Insurance**: Prior authorization (PA) is usually required, confirming HOA diagnosis and specialist involvement. Approval duration: up to 12 months.[5][8] - **Medicare Part D**: Program offers assistance; check Extra Help eligibility (income <150% FPL + assets <$17,550 single/$35,000 couple in 2025). New 2025 changes include $2,000 out-of-pocket cap and Prescription Payment Plan.[3][9] - **Uninsured**: Primary candidates for free medication. Submit insurance denial or proof of high co-pays if insured.[2] ## Step-by-Step Application Process 1. **Get Prescribed**: Ask your doctor (metabolic specialist) to confirm HOA via genetic testing or labs and write an Xuriden prescription.[4][5] 2. **Contact the Program**: Call BTG's partner, BioMatrix Specialty Pharmacy at **1-844-374-0604** (related Vistogard line; confirm for Xuriden) or visit RxAssist.org for BTG PAP details.[1][2] 3. **Complete Application**: Download from RxAssist or request via phone. Include: - Patient info (ID, income proof like tax returns/SSI). - Prescriber details and prescription. - Insurance cards (front/back) or denial letter.[10] 4. **Submit**: Fax, mail, or upload. Physician may handle via referral form.[1][10] 5. **Approval Notification**: Expect contact within days to weeks. ## Timeline and Delivery Processing: 1-4 weeks, depending on documentation. Once approved, medication ships directly from BioMatrix Specialty Pharmacy to your home or doctor's office. Refills auto-process if reauthorized; track via case manager.[1][2] ## Alternatives if Denied or Ineligible - **Appeal**: Provide additional income/clinical docs. - **Medicare Extra Help** or state programs.[3] - **Generic uridine** (if available; limited data).[6] - **Manufacturer co-pay cards** for insured patients. - **Patient Access Networks** or NeedyMeds.org for rare disease aid. - Switch to Vistogard if indication fits (emergency overdose), but not interchangeable.[7] No biosimilars exist; uridine triacetate is proprietary.[7] ## Important Disclaimer This guide is for informational purposes only and based on publicly available data as of 2026. Eligibility, processes, and thresholds can change—**always contact BTG PAP directly at 1-844-374-0604 or RxAssist.org for latest details**.[2] Not medical advice; consult your doctor. BTG International Inc. reserves rights to program changes. Word count: 1028.

Program information last verified: March 30, 2026